Table 1.

Patient demographics and adenoma classification

Group	Overall	− NSAID	+ NSAIDa
A. Sex
Male	50	25 (50%)	25 (50%)
Female	26	14 (54%)	12 (46%)
B. Age (yrs)
<40	2	2 (100%)	0 (0%)
40–65	43	26 (60%)	17 (40%)
>65	31	11 (35%)	20 (65%)
C. Polyp Type
TAb	61	29 (48%)	32 (52%)
TVc	15	10 (67%)	5 (33%)
FAPd	17	0 (0%)	17 (100%)
D. Dysplasiae
low grade	71	35 (49%)	36 (51%)
high grade	4	4 (100%)	0 (0%)
invasive	1	0 (0%)	1 (100%)
E. Size (mm)f
<10	23	9 (39%)	14 (61%)
10–30	46	26 (57%)	20 (43%)
>30	7	4 (57%)	3 (43%)

^aNSAID treatment is aspirin or ibuprofen for sporadic patients and sulinac for FAP patients, both for 1 year

^bTA, tubular adenoma

^cTV, tubulovillous adenoma; sporadic patients only

^dFamilial adenomatous polyposis (FAP) patients, no patient demographic or adenoma classification data available

^eDysplasia, P=0.12 between groups (two-tailed Fisher’s exact test)

^fSize, P=0.21 between groups (two-tailed Fisher’s exact test)